Tumor Hypoxia Imaging Agents in Nuclear Medicine
Trends in Peptide and Protein Sciences,
Vol. 1 No. 2 (2016),
17 January 2017
,
Page 38-40
https://doi.org/10.22037/tpps.v1i2.15322
Abstract
Hypoxia is due to imbalance in oxygen supply and oxygen demand compromising biological functions of cells. Since tumor hypoxia results in angiogenesis, apoptosis, metastasis, tumor aggressiveness and treatment failure, in vivo measurement is required. Nuclear imaging can provide information about tissue oxygen levels. 2-nitroimidazole containing compounds selectively accumulate in hypoxic cells. They have been radiolabeled with 18F, 123/124I, and 99mTc and used in clinical trial stages using PET and SPECT techniques. 62/64Cu-ATSM is a non-imidazole imaging agent, which is trapped in hypoxic cells. There is a great interest in the development of 99mTc-labeled 2-nitroimidazole compounds. Though novel compounds based on molecular mechanisms of hypoxia would be developed in future.
Highlights
- Tumor hypoxia results in angiogenesis, apoptosis, metastasis, tumor aggressiveness, and treatment failure.
- Nuclear imaging can provide information about tissue oxygen levels.
- 2-nitroimidazole compounds selectively accumulate in hypoxic cells.
- At present a few PET radiopharmaceuticals as hypoxia imaging agents are in clinical trial stages.
- Positron emission tomography (PET)
- Single photon emission computed tomography (SPECT)
- Hypoxia
- Nitroimidazoles
How to Cite
References
Aloj, L. and G. Morelli, (2004). ″Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy.″ Current Pharmaceutical Design, 10(24): 3009–31.
Krohn, K. A., Link, J. M. and R. P. Mason, (2008). ″Molecular Imaging of Hypoxia.″ Journal of Nuclear Medicine, 49(Suppl_2): 129S–148S.
Le, Q. T. and D. Courter, (2008). ″Clinical biomarkers for hypoxia targeting.″ Cancer Metastasis Reviews, 27(3): 351–62.
Linder, K. E., Chan, Y. W., Cyr, J. E., Malley, M. F., Nowotnik, D. P. and A. D. Nunn, (1994). ″TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidasecatalyzed reduction.″ Journal of Medicinal Chemistry, 37(1): 9–17.
Mason, R. P., Zhao, D., Pacheco-Torres, J., Cui, W., Kodibagkar, V. D., Gulaka, P. K., Hao, G., Thorpe, P., Hahn, E. W. and P. Peschke, (2010). ″Multimodality imaging of hypoxia in preclinical settings.″ The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 54(3): 259–80.
Mees, G., Dierckx, R., Vangestel, C. and C. Van de Wiele, (2009). ″Molecular imaging of hypoxia with radiolabelled agents.″ European Journal of Nuclear Medicine and Molecular Imaging, 36(10): 1674–86.
Schibli, R. and P.A. Schubiger, (2002). ″Current use and future potential of organometallic radiopharmaceuticals.″ European Journal of Nuclear Medicine and Molecular Imaging, 29(11): 1529–42.
Span, P.N. and J. Bussink, (2015). ″Biology of Hypoxia.″ Seminars in Nuclear Medicine, 45(2): 101–109.
Sun, X., Niu, G., Chan, N., Shen, B. and X. Chen, (2011). ″Tumor Hypoxia Imaging.″ Molecular Imaging and Biology, 13(3): 399–410.
Zhang, X., Su, Z. F., Ballinger, J. R., Rauth, A. M., Pollak, A. and J. R. Thornback, (2000). ″Targeting Hypoxia in Tumors Using 2-Nitroimidazoles with Peptidic Chelators for Technetium-99m: Effect of Lipophilicity.″ Bioconjugate Chemistry, 11(3): 401–407.
- Abstract Viewed: 881 times
- PDF Downloaded: 365 times